The Influence of Primary Cytomegalovirus or Epstein-Barr Virus Infection on the Course of Idiopathic Thrombocytopenic Purpura
- 831 Downloads
Idiopathic thrombocytopenic purpura (ITP) in children is usually triggered by a viral infections such as cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection. The aim of this study was to assess the frequency of CMV and EBV infections in children with first relapse of ITP, and the influence of these infections on the course and response to treatment of ITP. Sixty patients (30 boys and 30 girls) with ITP were enrolled into the study. We found that the age at the onset of ITP was from 1 month to 17 years (mean 7.0 ± 5.7 years), the platelet number was from 1 to 79 × 109/L (mean 18.1 ± 19.0 × 109/L) at the time of diagnosis and it increased from 17 to 395 × 109/L (mean 134.4 ± 81.2 × 109/L) (p < 0.05) after the first course of therapy. Forty seven patients required pharmacological treatment, the duration of the treatment was from 2 to 25 days (mean 6.1 ± 4.1 days). Relapses were observed in 27 (45 %) of the patients. Active CMV infection was found in 19 patients (31.7 %), EBV infection in 5 patients (8.3 %), and both infections concomitantly in 1 patient (1.7 %). The group of patients with CMV or EBV infection (n = 25) did not differ from the patients free of infection (n = 35) in regard to the age, number of platelets at onset, duration of treatment, number of platelets after treatment, number of relapses, and the interval between the onset and first relapse. In conclusion, active CMV or EBV infection is common in children with ITP. These infections do not seem to have an appreciable bearing on the clinical course and the response to treatment on children with ITP.
KeywordsChildren Cytomegalovirus Ebstein-Barr virus Idiopathic thrombocytopenic purpura Infection
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
- Adamowicz-Salach A, Chybicka A, Sawicz-Birkowska K (eds) (2008) Pediatric oncology and hematology. Wydawnictwo Lekarskie PZWL, Warsaw, pp 873–878Google Scholar
- Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, Milner R, Ali K, Barnard D, Bernstein M et al (1994) Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344(8924):703–707CrossRefPubMedGoogle Scholar
- Rodeghiero F (2008) First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. Eur J Haematol Vol 80 ( Suppl 69 ):19–26Google Scholar
- Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN (2009) Standarization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393CrossRefPubMedGoogle Scholar
- Walter RB, Hong TC, Bachli EB (2004) Life-threatening thrombocytopenia associated with acute Epstein- Barr virus infection in an older adult. Ann Hematol 81:672–675Google Scholar